

AI-powered tissue analysis: Consistent results. Confident diagnoses. Efficient workflows.

IVDR
CERTIFIED

Pathologists face growing challenges, balancing high diagnostic demands with limited time and increasing case volumes. Our Insight platform provides accuracy, consistency, and speed for evaluating various biomarkers across different indications, while integrating smoothly into existing workflows. Thus, it supports pathologists to work more confidently and efficiently, freeing up time for complex cases and deeper diagnostic insights.

The Insight advantages

- **Accuracy for patients - Confidence for pathologist**
Higher accuracy and reproducibility than the human eye is capable of. Freeing up resources across the lab.
- **Ready for your review**
Fully automated APPs - Results ready when you are. No manual interaction needed, only your review.
- **Precision that pays off**
Proven higher sensitivity in lymph node metastasis¹ detection or HER2 scoring² can save evaluation time, and reduce follow-up testing, saving time and money.
- **Quality matters - A decade of regulatory expertise**
Our first IVD certified APP was released in 2014. Today, we are the only company having all diagnostic APPs IVDR certified and with a zero-click workflow.
- **You'll never walk alone**
Experienced support team that gets you up and running quickly, and supports you along the way.
- **Precision first option**
For labs that are not yet digital, we offer a lightweight solution that supports the consistent assessment of predictive biomarkers.



Insight results displayed in the Sectra IDS7.


Integrations that actually work

Works with major PACS/IMS systems, including Proscia, Sectra, PathAI, Philips, Fujifilm, Corista, Smart in Media, and more.




Let our AI do the counting, so you can focus on the diagnosis.

Our AI-powered image analysis APPs deliver precise biomarker quantification across different cancer types. Fully automated zero-click workflows - integrated into your existing setup. Already in use by pathology labs in daily diagnosis.




HER2, breast cancer

Fully automated single-cell approach for HER2 Score assessment, bringing confidence to scoring also low expression cases.




Ki-67, breast cancer

Quantifies cell proliferation in invasive tissue, returning a proliferation index for the entire tumor region. Hotspot scoring is available optionally.




ER & PR, breast cancer

These two APPs measure ER and PR positivity and provide the percentage of positive cells, the total cell number as well as an Allred score.




PD-L1, lung cancer (NSCLC)

Evaluates whole tumor sections and returns the Tumor Proportion Score (TPS), ensuring objective PD-L1 expression analysis.



Lymph node metastasis, breast & colon cancer

Identifies even small and hard-to-spot metastases in lymph nodes (H&E), enhancing sensitivity and reducing the need for additional IHC staining¹.



Prostate cancer, detection and grading, H&E (IVDD)

Detects invasive tumor areas in prostate needle core biopsies and provides automated Gleason scoring, ensuring objective and reproducible grading.



References

- 1) Dooijeweert et al., 2024
- 2) Parry et al., 2026

Ready to bring confidence and reproducibility to your biomarker assessment? Scan to learn more.



Stay confident

